Findings showed 46.4% of patients treated with upadacitinib 15 mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has ...

AbbVie recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.

Findings showed 46.4% of patients treated with upadacitinib 15mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has approved ...

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis. AbbVie on Tuesday said the European Commission's nod ...

If approved, upadacitinib would be the first and only oral advanced therapy for adults living with GCA. "Giant cell arteritis is an inflammatory disease that, if left untreated, can lead to severe ...

Giant cell arteritis (GCA) is a medical emergency ... Epitheloid cells in the granuloma cause injury to the arterial wall by secreting matrix metalloproteinases and reactive oxygen and nitrogen ...

SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck. Symptoms include ...

Giant cell arteritis (GCA) is a medical emergency ... disease-modifying therapy is indicated in relapsing disease. Granuloma formation within media. CD4 + T cells secrete IFN-γ and TNF-α ...

The company is seeking approval for once-daily Rinvoq (15 mg) for treating adult patients with giant cell arteritis (GCA), an autoimmune disease-causing inflammation of the large arteries.

As other immunology players make inroads into the giant cell arteritis (GCA) arena, one of Johnson & Johnson’s top-grossing medicines, Tremfya, has come up short in the disease. J&J has nixed ...

On Thursday, AbbVie said that Rinvoq, also known as upadacitinib, met its primary endpoint in the SELECT-GCA trial in patients with giant cell arteritis (GCA). Specifically, 46% of patients ...

According to results of the study, 46% of patients with giant cell arteritis administered Rinvoq achieved sustained remission from weeks 12 to 52. Results from the Phase III SELECT-GCA study ...